Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
258.4 EUR | -21.92% | 0.00% | 0.00% |
21/05 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
21/05 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
Sales 2024 * | 19.8B 2.88B 2.65B 240B | Sales 2025 * | 23.62B 3.43B 3.16B 286B | Capitalization | 125B 18.14B 16.7B 1,511B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 679M 626M 56.6B | Net income 2025 * | 6.61B 961M 886M 80.11B | EV / Sales 2024 * | 4.99 x |
Net cash position 2024 * | 25.9B 3.77B 3.47B 314B | Net cash position 2025 * | 32.35B 4.7B 4.33B 392B | EV / Sales 2025 * | 3.91 x |
P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.4
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 day | -21.92% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 01/99/01 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01/07/01 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23/20/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01/17/01 |
Director/Board Member | 73 | 01/03/01 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01/16/01 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-0.99% | 21.83B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B | |
-30.73% | 7.6B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock